经肝动脉沙培林碘化油乳剂治疗原发性肝癌临床观察

Preliminary Clinical Observations on Transarterial Immuno embolization with an Emulsion of Sapylin and Lipiodol in Treating Primary Liver Cancer

目的 评价免疫栓塞制剂在临床治疗肝癌的安全性和对免疫的调节作用。方法 对 16例原发性肝癌病人经瘤体供血动脉注入沙培林碘化油乳剂行免疫栓塞治疗 ,治疗前后用流式细胞仪测定淋巴细胞亚群的比例 ,并评价AFP、影像学等临床疗效指标。结果 治疗后患者的CD3+ 、CD4+ 、NK细胞比例、CD4+ /CD8+ 比值由治疗前的 45 .8%、2 6 .5 %、12 .6 %和 1.0 3分别提高到 5 6 .5 %、36 .8%、16 .4%和 1.46。治疗后的主要副作用为发热 (10 0 % )、低血压 (6 8.8% )、白细胞计数增加和淋巴细胞百分比下降。结论 免疫栓塞治疗对原发性肝癌是一种安全有效的治疗方法 ,同时可改善肝癌患者的细胞免疫状态。

Objective To evaluate the safety and immune regulative efficacy of transarterial immuno embolization (TIE) with an emulsion of Sapylin and Lipiodol in treating patients with primary liver cancer.Methods 16 patients with PLC were treated with Sapylin lipiofol emulsion via tumor feeding arteries. The peripheral blood lymphcyte subsets proportions were assayed by flow cytometer, and the clinical therapeutic effect parameters such as AFP and radiological findings were evaluated before and after the treatment.Results Fever (100%)and hypotension (68.8%) were the main side effects of the therapy. The increase of WBC count and the decrease of lymphocyte percentage were observed. The main immunological parameters of CD3 +?CD4 +?CD8 +?NK cell proportions and CD4 +/CD8 + radio increased significantly from 45.8%, 26.5%, 12.6% and 1.03 before therapy to 56.5%, 36.8%, 16.4% and 1.46 after therapy, respectively.Conclusion TIE is a safe and effective therapeutic modality in treating PLC, and it can improve the cellular immune state of the patients with PLC significantly.